This is a working overview of GW501516, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic PPARδ agonist | Not a steroid or a selective androgen receptor modulator. |
| Common synonyms | Cardarine, GW501516, GW-501516, endurobol | Names vary by supplier and literature source. |
| Appearance | White to off-white powder | Consistent with many small-molecule research chemicals. |
| Solubility | Low in water; soluble in DMSO and ethanol | Often prepared in organic solvent for laboratory work. |
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid and energy metabolism. |
Laboratory detection of cardarine typically involves sample preparation followed by chromatographic separation and mass spectrometric identification. Urine is the most common matrix for anti-doping tests, though blood and hair have also been explored. Methods can target the parent compound or its metabolites, depending on the expected window of detection. Reference standards are required for accurate quantification. Matrix effects and dilution can influence results, so laboratories use internal standards and validation protocols. The exact detection window varies with dose, route, and individual metabolism.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Responses lasted for at least six months in 78% of responders. Because the clinical trial was fairly small, Merck is obligated to conduct further post-marketing studies to ensure that the results are valid. Pembrolizumab was granted orphan drug designation for small-cell lung cancer in October 2017. In June 2018, the US FDA approved pembrolizumab for use in both advanced cervical cancer for PD-L1 positive patients and for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or who have relapsed after two or more prior lines of therapy. In August 2018, the US FDA updated the prescribing information for pembrolizumab to require the use of an FDA-approved companion diagnostic test to determine PD-L1 levels in tumor tissue from patients with locally advanced or metastatic urothelial cancer who are cisplatin-ineligible. On 16 August 2018, the FDA approved the Dako PD-L1 IHC 22C3 PharmDx Assay (Dako North America, Inc.) as a companion diagnostic to select patients with locally advanced or metastatic urothelial carcinoma who are cisplatin-ineligible for treatment with pembrolizumab. The 22C3 assay determines PD-L1 expression by using a combined positive score (CPS) assessing PD-L1 staining in tumor and immune cells.
=== Structural analysis software === NASA software engineers have created thousands of computer programs over the decades equipped to design, test, and analyze stress, vibration, and acoustical properties of a broad assortment of aerospace parts and structures. The NASA Structural Analysis Program, or NASTRAN, is considered one of the most successful and widely used NASA software programs. It has been used to design everything from Cadillacs to roller coaster rides. Originally created for spacecraft design, it has been employed in a host of non-aerospace applications and is available to industry through NASA's Computer Software Management and Information Center (COSMIC). COSMIC maintains a library of computer programs from NASA and other government agencies and sells them at a fraction of the cost of developing a new program. NASA Structural Analysis Computer Software was inducted into the Space Foundation Space Technology Hall of Fame in 1988.
==== MeSH D13.570.685 – pyrimidine nucleosides ==== MeSH D13.570.685.245 – cytidine MeSH D13.570.685.245.217 – azacitidine MeSH D13.570.685.245.453 – cytarabine MeSH D13.570.685.245.453.050 – ancitabine MeSH D13.570.685.245.500 – deoxycytidine MeSH D13.570.685.245.500.250 – bromodeoxycytidine MeSH D13.570.685.245.500.950 – zalcitabine MeSH D13.570.685.245.500.950.500 – lamivudine MeSH D13.570.685.350 – formycins MeSH D13.570.685.350.200 – coformycin MeSH D13.570.685.350.200.700 – pentostatin MeSH D13.570.685.705 – thymidine MeSH D13.570.685.705.875 – stavudine MeSH D13.570.685.705.900 – trifluridine MeSH D13.570.685.705.950 – zidovudine MeSH D13.570.685.725 – tunicamycin MeSH D13.570.685.852 – uridine MeSH D13.570.685.852.150 – arabinofuranosyluracil MeSH D13.570.685.852.176 – azauridine MeSH D13.570.685.852.250 – 3-deazauridine MeSH D13.570.685.852.300 – deoxyuridine MeSH D13.570.685.852.300.150 – bromodeoxyuridine MeSH D13.570.685.852.300.350 – floxuridine MeSH D13.570.685.852.300.400 – idoxuridine MeSH D13.570.685.852.628 – pseudouridine MeSH D13.570.685.852.800 – tetrahydrouridine MeSH D13.570.685.852.829 – thiouridine
Sources: en.wikipedia.org
2,5-Dimethoxy-4-propylamphetamine (DOPR) is a psychedelic drug of the phenethylamine, amphetamine, and DOx families related to DOM. It is the derivative of DOM in which the methyl group at the 4 position has been replaced with a propyl group. The drug is taken orally. The drug acts as a serotonin receptor agonist, including of the serotonin 5-HT2A receptor. It produces psychedelic-like effects in animals. DOPR was first described in the literature by Alexander Shulgin in 1970. Subsequently, it was described in greater detail by Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
=== Nancy Bartlett === Nancy Lynn Bartlett is played by Sandra Bernhard. Nancy is a part owner of the Lanford Lunch Box. She marries Arnie Thomas, but — after he eventually leaves her — she comes out as a lesbian. She frequently is seen dating women; her first girlfriend Marla is played by Morgan Fairchild. Nancy is never ashamed of her promiscuity, nor does she ever show any self-consciousness about her unusual behavior. She is one of the most self-confident characters in the series, often even more than Roseanne. Her tendency toward self-absorption seems to only be quelled while dating a woman or being around Jackie. Nancy turns out to be a loyal good friend to both Roseanne and Jackie throughout the series; however, she doesn't hesitate to reprimand them for their selfishness and cruelty when they treat their mother, Bev, so harshly that Bev ends up crying about it for days afterward while Nancy gives her support. Nancy appeared in a revival-era episode in 2018 in season 10, but did not appear on The Conners.
=== Transmetallation === The transmetallation of the trans intermediate from the oxidative addition step is believed to proceed via a variety of mechanisms depending on the substrates and conditions. The most common type of transmetallation for the Stille coupling involves an associative mechanism. This pathway implies that the organostannane, normally a tin atom bonded to an allyl, alkenyl, or aryl group, can coordinate to the palladium via one of these double bonds. This produces a fleeting pentavalent, 18-electron species, which can then undergo ligand detachment to form a square planar complex again. Despite the organostannane being coordinated to the palladium through the R2 group, R2 must be formally transferred to the palladium (the R2-Sn bond must be broken), and the X group must leave with the tin, completing the transmetalation. This is believed to occur through two mechanisms. First, when the organostannane initially adds to the trans metal complex, the X group can coordinate to the tin, in addition to the palladium, producing a cyclic transition state. Breakdown of this adduct results in the loss of R3Sn-X and a trivalent palladium complex with R1 and R2 present in a cis relationship. Another commonly seen mechanism involves the same initial addition of the organostannane to the trans palladium complex as seen above; however, in this case, the X group does not coordinate to the tin, producing an open transition state. After the α-carbon relative to tin attacks the palladium, the tin complex will leave with a net positive charge.
=== United States === In May 2025, the national survey Rasmussen Reports reported that 57% of Americans supported an attack on Iran. Former chief negotiator and Secretary of State John Kerry commended Trump's effort and compared the negotiations to "Khomeini poisoned chalice". White House Press Secretary Karoline Leavitt has stated that should Iran develop nukes, there will be "all hell to pay". On April 18, Secretary of State Marco Rubio urged European countries to quickly decide on reimposing sanctions against Iran, warning that Iran is violating the existing agreement and nearing the capability to develop a nuclear weapon. Rubio later also said Iran can have a civilian nuclear energy program instead of a military WMD atomic weapons program. Secretary of Defense Pete Hegseth and national security advisor Mike Waltz were reportedly divided on whether US military should attack Iran. Trump told reporters he was in no rush to attack Iran and it still has a chance to "live happily without death". He also said the US would lead the pack in possibly attacking Iran and that there are only two alternatives, bombing them viciously or nicely, and that he was still undecided. Former special representative for Iran Elliott Abrams argued that Trump did not seek war. However, should the talks fail, Iran's nuclear program should be destroyed by Israel and/or the US Political commentator Tucker Carlson argued this was the worst time for US military intervention in Iran.
Sources: en.wikipedia.org
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.
It binds to and activates PPARδ, a nuclear receptor that regulates genes related to fatty acid oxidation and energy use. This activation alters transcription in tissues such as skeletal muscle and liver. The full range of downstream effects in humans is not fully established.
No, cardarine is not known to occur naturally in plants, animals, or humans. It is a synthetic molecule produced for laboratory research. Products labeled as cardarine should therefore be treated as manufactured chemicals with variable purity.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.